Condition

Stable COPD Patients

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common interventions4

Lead sponsors shown3

Clinical trials

3 shown

Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAsNCT07131020 · 2024-05-11

RECRUITING

Effect of Vitamin D3 on Lung Function and Exercise Tolerance in COPD PatientsNCT03781895 · 2017-03-01

COMPLETED

Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC StudyNCT02789540 · 2016-06-10

COMPLETED

Common interventions

CholecalciferolDRUG1 Conventional Western medicine treatmentDRUG1 TCM syndrome differentiation treatmentDRUG1 Yifei moxibustionBEHAVIORAL1

Leading sponsors

AstraZeneca 1 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 1 Henan University of Traditional Chinese Medicine 1

Trial status mix

COMPLETED2

RECRUITING1

Phase mix

NA1

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.